A
Alterome Therapeutics
A biopharmaceutical company developing alteration-specific targeted therapies
About Alterome Therapeutics
Alterome is a startup that operates in the healthcare sector, specifically in the field of oncology. The company's primary objective is to transform the lives of cancer patients by discovering precise therapies that inspire hope. They aim to accelerate the development of targeted therapies using a structure-guided drug discovery approach. This approach allows them to design alteration-specific therapies that precisely target high-value, validated oncogenic drivers, providing treatment options for patients who have very few alternatives.
Read full description
Alterome serves a critical market segment - cancer patients who are in desperate need of effective treatment options. The company's business model revolves around the research, development, and commercialization of targeted therapies for cancer. They generate revenue through the successful development and sale of these therapies.
The company prides itself on its team of dedicated scientists and business professionals. Unlike traditional top-down companies, Alterome operates on a co-elevation model, where everyone's opinions, knowledge, and experience are valued. This collaborative approach, coupled with their commitment to integrity, empathy, and humility, is what they believe will enable them to achieve their mission.
In summary, Alterome is a patient-focused company that is dedicated to discovering precise, targeted therapies for cancer. They operate in a collaborative, respectful environment where everyone's contributions are valued, and they believe that this approach will enable them to succeed in their mission.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Diego, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 68.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Small Molecules, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2024 | $132M | $528M | Goldman Sachs · Invus · OrbiMed · Blue Owl Capital | ↗ |
| SERIES AOther financing | Nov 2022 | $35M | $320M | Boxer Capital · OrbiMed · Vida Ventures · Nextech Invest | ↗ |
Growth signals
Latest recorded traffic for Alterome Therapeutics is 2.4K monthly website visits, down 40% over the last three months. Alterome Therapeutics's team declined 7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
OrbiMed
Vida Ventures
Boxer Capital
Nextech Invest
Colt Ventures
Goldman Sachs
Invus
Blue Owl Capital
Canaan
Driehaus Capital Management
Digitalis Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alterome Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alterome Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.